Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 05 April 2012
A new piece of legislation released in discussion draft form by the Senate Health, Education, Labor and Pensions Committee aims to "overhaul" the US Food and Drug Administration's (FDA) Accelerated Approval pathways, reports The Hill.
Among other things, the bill would "create a new 'breakthrough' designation to provide more flexibility and certainty for developers of new medicines intended to address serious or life-threatening diseases or conditions," reports The Hill.
The draft legislation, released 4 April 2012, also includes the Advancing Breakthrough Therapies for Patients Act (ABTPA) bill released 27 March by Sens. Michael Bennet (D-CO), Richard Burr (R-NC) and Orrin Hatch (R-UT).
That legislation would "expedite FDA approval and provide more flexibility when a drug or treatment shows dramatic responses early in development, while still ensuring drug safety and efficacy," said the Senators in a statement.
The draft legislation is slated to be tacked on to the reauthorization of the Prescription Drug User Fee Act (PDUFA) legislation that must be approved before 30 September if the agency is to maintain its current level of funding.
The Hill - Senate Health panel floats proposal for speedy FDA approval of life-saving drugs
Discussion draft: To amend the Federal Food, Drug, and Cosmetic Act with respect to certain reauthorizations
Regulatory Focus - Senators Draft Bill to Expedite Drug Approval
See all Regulatory Focus news stories about PDUFA.
Tags: Accelerated Approval Pathway, Legislation, Latest News, pharmaceutical, draft, drug, PDUFA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.